Monte Rosa Therapeutics Inc
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
(0.0% 1d) (-16.2% 1m) (-11.2% 1y) (0.0% 2d) (-4.3% 3d) (-19.6% 7d) (-14.89% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 297,389,500
https://www.monterosatx.com
Sec Filling | Patents | 60 employees
Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
drug discovery profitable computational machine learning
add to watch list Paper trade email alert is off
Press-releases
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -7.02%
rosa year update therapeutics financial results
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: 1.27%
H: 8.79%
C: -2.35%
mrt-8102 rosa enabling therapeutics molecular
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-01-31 (Crawled : 12:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: -1.13%
H: 8.94%
C: 0.67%
rosa therapeutics
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: 4.07%
H: 10.43%
C: 9.91%
rosa update key therapeutics
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: 0.88%
H: 2.17%
C: -0.69%
conference rosa therapeutics
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
Published: 2023-11-21 (Crawled : 12:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: -1.54%
H: 0.0%
C: -6.88%
conference rosa therapeutics
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-09 (Crawled : 12:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: -0.54%
H: 3.0%
C: -10.08%
rosa update therapeutics financial results
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
Published: 2023-11-07 (Crawled : 15:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: 1.81%
H: 8.88%
C: 5.03%
mrt-6160 rosa treat preclinical therapeutics potential molecular
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Published: 2023-10-27 (Crawled : 11:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: -1.2%
H: 15.35%
C: 12.55%
rosa therapeutics
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
Published: 2023-10-26 (Crawled : 21:00) - globenewswire.com
GLUE | $5.93 2.24% 2.19% 190K
|
Professional, Scientific, and T...
|
| O: -1.2%
H: 15.35%
C: 12.55%
nasdaq rosa direct therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10